ATE505481T1 - Fusionsproteine der tnf-superfamilie - Google Patents
Fusionsproteine der tnf-superfamilieInfo
- Publication number
- ATE505481T1 ATE505481T1 AT07801940T AT07801940T ATE505481T1 AT E505481 T1 ATE505481 T1 AT E505481T1 AT 07801940 T AT07801940 T AT 07801940T AT 07801940 T AT07801940 T AT 07801940T AT E505481 T1 ATE505481 T1 AT E505481T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- tnf superfamily
- present
- fusion protein
- tnfsf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06017891A EP1894940A1 (en) | 2006-08-28 | 2006-08-28 | TNF superfamily fusion proteins |
| PCT/EP2007/007517 WO2008025516A2 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505481T1 true ATE505481T1 (de) | 2011-04-15 |
Family
ID=37836940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07801940T ATE505481T1 (de) | 2006-08-28 | 2007-08-28 | Fusionsproteine der tnf-superfamilie |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8147843B2 (OSRAM) |
| EP (2) | EP1894940A1 (OSRAM) |
| JP (1) | JP5274464B2 (OSRAM) |
| AT (1) | ATE505481T1 (OSRAM) |
| AU (1) | AU2007291490A1 (OSRAM) |
| CA (2) | CA2661599C (OSRAM) |
| DE (1) | DE602007013920D1 (OSRAM) |
| WO (1) | WO2008025516A2 (OSRAM) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072903B1 (en) | 2007-07-10 | 2017-10-25 | Apogenix AG | Tnf superfamily collectin fusion proteins |
| EP2310409A2 (en) * | 2008-06-17 | 2011-04-20 | Apogenix GmbH | Multimeric tnf receptors |
| JP5665739B2 (ja) * | 2008-07-14 | 2015-02-04 | ドイチェス クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ | 炎症性疾患を治療するためのｃｄ９５インヒビターの使用 |
| EP3103875A1 (en) | 2008-07-21 | 2016-12-14 | Apogenix AG | Tnfsf single chain molecules |
| JP5844158B2 (ja) | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| EP2877205A4 (en) | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| NO2776305T3 (OSRAM) | 2014-04-23 | 2018-01-27 | ||
| BR102014031185A8 (pt) * | 2014-12-12 | 2021-05-04 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp | proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer |
| KR102435324B1 (ko) | 2015-01-20 | 2022-08-23 | 아이쥐엠 바이오사이언스 인코포레이티드 | 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도 |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
| JP6884785B2 (ja) | 2015-09-23 | 2021-06-09 | アポジェニックス アーゲー | 抗ｃｄ９５ｌ抗体 |
| WO2017081082A2 (en) * | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| EP3565888A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| EP3565586B1 (en) | 2017-01-06 | 2025-10-08 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| MA50871A (fr) | 2017-05-10 | 2020-03-18 | Iovance Biotherapeutics Inc | Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques |
| JP2020522516A (ja) | 2017-06-05 | 2020-07-30 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法 |
| WO2019032952A1 (en) | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE |
| AU2018368786B2 (en) | 2017-11-17 | 2025-05-22 | Iovance Biotherapeutics, Inc. | TIL expansion from fine needle aspirates and small biopsies |
| JP2021503885A (ja) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養 |
| JP7565795B2 (ja) | 2017-12-15 | 2024-10-11 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法 |
| KR20200119242A (ko) | 2018-01-08 | 2020-10-19 | 이오반스 바이오테라퓨틱스, 인크. | 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법 |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| MA51875A (fr) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics Inc | Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine |
| EA202092319A1 (ru) | 2018-03-29 | 2021-03-04 | Айовэнс Байотерапьютикс, Инк. | Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии |
| TW202446952A (zh) | 2018-04-27 | 2024-12-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途 |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| SG11202101787XA (en) | 2018-09-20 | 2021-04-29 | Iovance Biotherapeutics Inc | Expansion of tils from cryopreserved tumor samples |
| ES3021682T3 (en) | 2018-11-05 | 2025-05-27 | Iovance Biotherapeutics Inc | Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies |
| CN113272421B (zh) | 2018-11-05 | 2025-02-18 | 艾欧凡斯生物治疗公司 | 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途 |
| JP2022506508A (ja) | 2018-11-05 | 2022-01-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養 |
| MX2021004953A (es) | 2018-11-05 | 2021-08-11 | Iovance Biotherapeutics Inc | Seleccion de celulas t reactivas al tumor mejoradas. |
| US20220193131A1 (en) | 2018-12-19 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof |
| SG11202109331QA (en) | 2019-03-01 | 2021-09-29 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2020205662A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Inc. | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| KR20220122639A (ko) | 2019-11-27 | 2022-09-02 | 미스트 쎄라퓨틱스, 엘엘씨 | 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법 |
| CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| KR20220158727A (ko) | 2020-02-27 | 2022-12-01 | 미스트 쎄라퓨틱스, 엘엘씨 | 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물 |
| CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| EP4146793A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| JP2023538667A (ja) * | 2020-08-24 | 2023-09-08 | サノフィ パスツール インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２感染症に対するワクチン |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| JP2024501452A (ja) | 2020-12-11 | 2024-01-12 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療 |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| AR126323A1 (es) | 2021-03-05 | 2023-10-04 | Iovance Biotherapeutics Inc | Composiciones para el almacenamiento de tumores y cultivos celulares |
| IL307800A (en) | 2021-04-19 | 2023-12-01 | Iovance Biotherapeutics Inc | Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| CN117396520A (zh) * | 2021-05-27 | 2024-01-12 | 北京安信怀德生物技术有限公司 | 包含两个trail三聚体的超trail分子 |
| TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者 |
| JP2024534581A (ja) | 2021-09-24 | 2024-09-20 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤 |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| EP4469066A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001260633A1 (en) * | 2000-05-26 | 2001-12-03 | Mochida Pharmaceutical Co., Ltd. | Fas ligand-fused proteins |
-
2006
- 2006-08-28 EP EP06017891A patent/EP1894940A1/en not_active Withdrawn
-
2007
- 2007-08-28 AT AT07801940T patent/ATE505481T1/de not_active IP Right Cessation
- 2007-08-28 JP JP2009525967A patent/JP5274464B2/ja not_active Expired - Fee Related
- 2007-08-28 CA CA2661599A patent/CA2661599C/en not_active Expired - Fee Related
- 2007-08-28 AU AU2007291490A patent/AU2007291490A1/en not_active Abandoned
- 2007-08-28 EP EP07801940A patent/EP2069392B1/en not_active Not-in-force
- 2007-08-28 DE DE602007013920T patent/DE602007013920D1/de active Active
- 2007-08-28 US US12/439,486 patent/US8147843B2/en not_active Expired - Fee Related
- 2007-08-28 WO PCT/EP2007/007517 patent/WO2008025516A2/en not_active Ceased
- 2007-08-28 CA CA2860945A patent/CA2860945C/en not_active Expired - Fee Related
-
2012
- 2012-02-23 US US13/403,826 patent/US8580273B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2860945A1 (en) | 2008-03-06 |
| US20110027218A1 (en) | 2011-02-03 |
| US8147843B2 (en) | 2012-04-03 |
| EP2069392A2 (en) | 2009-06-17 |
| EP2069392B1 (en) | 2011-04-13 |
| AU2007291490A1 (en) | 2008-03-06 |
| JP2010501191A (ja) | 2010-01-21 |
| WO2008025516A2 (en) | 2008-03-06 |
| CA2661599C (en) | 2015-06-09 |
| US8580273B2 (en) | 2013-11-12 |
| WO2008025516A3 (en) | 2008-04-17 |
| CA2860945C (en) | 2015-12-29 |
| US20120148527A1 (en) | 2012-06-14 |
| JP5274464B2 (ja) | 2013-08-28 |
| DE602007013920D1 (de) | 2011-05-26 |
| CA2661599A1 (en) | 2008-03-06 |
| EP1894940A1 (en) | 2008-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE505481T1 (de) | Fusionsproteine der tnf-superfamilie | |
| WO2009007120A3 (en) | Tnf superfamily collectin fusion proteins | |
| WO2010003766A3 (en) | Multimeric tnf receptors | |
| WO2009068627A3 (en) | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same | |
| WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
| EP2604693A3 (en) | TNFSF single chain molecules | |
| BR0315327A (pt) | Antagonistas de il-15 | |
| DK1767546T3 (da) | Angiogenese-inhiberende kimært protein og dets anvendelse | |
| PH12015500806A1 (en) | Binding molecules to the human ox40 receptor | |
| NO20053872D0 (no) | Fusjonskonstruksjoner og anvendelse av disse for fremstilling av antistoffer med okt FC-reseptorbindingsaffinitet og effektorfunksjon. | |
| WO2008066752A3 (en) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| ATE533782T1 (de) | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür | |
| BR0315652A (pt) | Molécula de ácido nucleico isolada, vetor, sistema de vetor-hospedeiro, método de produção de um polipeptìdeo de fusão, ácido nucleico isolado, polipeptìdeo de fusão, e, multìmero | |
| NO20062886L (no) | IL-23 og dens reseptor, beslektede reagenser og fremgangsmater | |
| ECSP12011698A (es) | Anticuerpos cea | |
| WO2008077945A3 (en) | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies | |
| EP3461844A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders | |
| DK1888641T3 (da) | Serumalbuminbindende proteiner | |
| WO2010020766A3 (en) | Interleukin fusion polypeptides | |
| WO2008074839A3 (en) | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders | |
| WO2009095489A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
| MY150226A (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| WO2004094651A3 (en) | Novel human polypeptides encoded by polynucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |